MXPA04008681A - Compuestos oxo-azabiciclicos. - Google Patents

Compuestos oxo-azabiciclicos.

Info

Publication number
MXPA04008681A
MXPA04008681A MXPA04008681A MXPA04008681A MXPA04008681A MX PA04008681 A MXPA04008681 A MX PA04008681A MX PA04008681 A MXPA04008681 A MX PA04008681A MX PA04008681 A MXPA04008681 A MX PA04008681A MX PA04008681 A MXPA04008681 A MX PA04008681A
Authority
MX
Mexico
Prior art keywords
description
inclusive
integer
formula
group
Prior art date
Application number
MXPA04008681A
Other languages
English (en)
Inventor
Wen-Song Yue
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA04008681A publication Critical patent/MXPA04008681A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto seleccionado de aquellos de la formula (I):(ver formula I)en donde: X1, X2 y X3 representan N o -CR3 en donde R3 es lo descripto en la memoria descriptiva, G1 representa un grupo seleccionado de aquellos de las formulas (i/a) e (i/b):(ver formulas)en donde R4, R5, y R6 son lo definido anteriormente, G2 representa un grupo seleccionado de enlace triple de carbono-carbono, CH=C=CH-, C=O, C=S, S(O)n1 en donde n1 representa un numero entero de 0 a 2 inclusive, y un grupo de la formula (i/c):(ver formula)en donde Y1 representa O, S, -NH o -N alquilo e Y2 representa O, S, -NH o -N alquilo, n es un numero entero de 0 a 6 inclusive, y m es un numero entero de 0 a 7 inclusive, Z1 representa -CR9R10, en donde R9 y R10 son lo definido en la memoria descriptiva, A representa un sistema de anillo, R1 representa un grupo seleccionado de H, alquilo, alquenilo, alquinilo, optativamente sustituido y el grupo de la formula (i/d):(ver formula)en donde p, Z2, B, q y G2 son lo definido en la memoria descriptiva y optativamente, sus isomeros opticos, N-oxidos y sales de ellos con el acido o base farmaceuticamente aceptable, y productos medicinales que contienen los mismos son utiles como inhibidores especificos de la metaloproteasa de la matriz de tipo 13.
MXPA04008681A 2002-03-08 2003-03-06 Compuestos oxo-azabiciclicos. MXPA04008681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds
PCT/EP2003/002277 WO2003076417A2 (en) 2002-03-08 2003-03-06 Oxo-azabicyclic compounds

Publications (1)

Publication Number Publication Date
MXPA04008681A true MXPA04008681A (es) 2004-12-06

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04008681A MXPA04008681A (es) 2002-03-08 2003-03-06 Compuestos oxo-azabiciclicos.

Country Status (25)

Country Link
EP (1) EP1492775A2 (es)
JP (1) JP2005526070A (es)
KR (1) KR20040095270A (es)
CN (1) CN1738806A (es)
AP (1) AP2004003125A0 (es)
AR (1) AR039562A1 (es)
AU (2) AU2002249275A1 (es)
BR (1) BR0308280A (es)
CA (1) CA2478706A1 (es)
CO (1) CO5601020A2 (es)
EA (1) EA200401053A1 (es)
EC (1) ECSP045278A (es)
IL (1) IL163818A0 (es)
IS (1) IS7414A (es)
MA (1) MA27183A1 (es)
MX (1) MXPA04008681A (es)
NO (1) NO20044041L (es)
OA (1) OA12782A (es)
PA (1) PA8568501A1 (es)
PE (1) PE20031018A1 (es)
PL (1) PL372622A1 (es)
SV (1) SV2003001495A (es)
TN (1) TNSN04169A1 (es)
UY (1) UY27700A1 (es)
WO (2) WO2003076416A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003253176A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
WO2004014868A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CA2564085C (en) * 2004-04-30 2013-04-02 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
JP2008502666A (ja) * 2004-06-15 2008-01-31 アストラゼネカ アクチボラグ 抗癌剤としての置換キナゾロン類
JP2010505881A (ja) 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
MX2018003563A (es) 2015-09-23 2018-06-18 Janssen Pharmaceutica Nv Nuevos compuestos.
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513394A (ja) * 1996-12-17 2002-05-08 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性のキナゾリノン類
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Also Published As

Publication number Publication date
CN1738806A (zh) 2006-02-22
ECSP045278A (es) 2004-10-26
KR20040095270A (ko) 2004-11-12
PA8568501A1 (es) 2003-12-19
AU2003212307A1 (en) 2003-09-22
CO5601020A2 (es) 2006-01-31
IS7414A (is) 2004-08-19
MA27183A1 (fr) 2005-01-03
JP2005526070A (ja) 2005-09-02
IL163818A0 (en) 2005-12-18
BR0308280A (pt) 2004-12-28
AP2004003125A0 (en) 2004-09-30
WO2003076417A2 (en) 2003-09-18
PL372622A1 (en) 2005-07-25
WO2003076416A1 (en) 2003-09-18
AR039562A1 (es) 2005-02-23
UY27700A1 (es) 2003-10-31
TNSN04169A1 (fr) 2007-03-12
AU2002249275A1 (en) 2003-09-22
EA200401053A1 (ru) 2005-04-28
OA12782A (en) 2006-07-10
EP1492775A2 (en) 2005-01-05
PE20031018A1 (es) 2004-01-09
NO20044041L (no) 2004-10-07
CA2478706A1 (en) 2003-09-18
WO2003076417A3 (en) 2003-11-13
SV2003001495A (es) 2003-11-04

Similar Documents

Publication Publication Date Title
MXPA04008681A (es) Compuestos oxo-azabiciclicos.
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
MXPA03007249A (es) Compuestos triazolo como inhibidores de mmp.
ATE297203T1 (de) Antithrombotische mitteln
ATE306261T1 (de) Antithrombosemittel
CY1110355T1 (el) Ενεργοποιητης του ενεργοποιουμενου απο πολλαπλασιαστη υπεροξυσωματων υποδοχεα δ
DE69919212D1 (de) Aromatische amiden
SE0102616D0 (sv) Novel compounds
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
HUP0203453A2 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
CY1107634T1 (el) Φαρμακευτικη συνθεση
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
ZA9610418B (en) Phenylimidazolidines containing in particular a nitrooxy or carbonyloxy radical, preparation process and intermediates, use as medicaments, new uses and pharmaceutical compositions.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
MXPA04003008A (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa 13 de la matriz.
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
DE60229054D1 (de) Synthese von zyklopentadien derivaten
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
ATE308540T1 (de) Antithrombosemittel
AR044175A1 (es) Compuestos de cefemo
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
SE0003186D0 (sv) New process
MXPA04003086A (es) Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.